All In Biotech

Drug Trial Radar · NCT05480306

Phase 2 Study of DKN-01 in Colorectal Cancer

Randomized Phase 2 Study of DKN-01 Plus FOLFIRI/FOLFOX and Bevacizumab Versus FOLFIRI/FOLFOX and Bevacizumab as Second-line Treatment of Advanced Colorectal Cancer (DeFianCe)

Last checked: Nov 19, 2026Latest source record: Aug 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 188 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

188

Actual

Start

Aug 30, 2022

Primary completion

Jul 10, 2025

Study completion Jul 10, 2025

Sponsor

Lead sponsor
Leap Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Jul 29, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2 randomized, open-label, two-part, multicenter study with a safety run-in to evaluate efficacy and safety of DKN-01 plus FOLFIRI/FOLFOX and bevacizumab versus standard of care (SOC) \[FOLFIRI/FOLFOX and bevacizumab\] as second-line treatment of advanced CRC patients.

Conditions

  • Colorectal Cancer
  • Colorectal Adenocarcinoma
  • Colo-rectal Cancer
  • Colorectal Cancer Metastatic

Interventions

  • DKN-01Drug

    30 minute IV infusion (400mg) every two weeks with an additional loading dose in the first cycle of treatment

  • FOLFIRIDrug

    90-min IV infusion of irinotecan, leucovorin, and fluorouracil followed by a continuous 46-hour infusion of fluorouracil every two weeks

  • BevacizumabDrug

    90-min IV infusion (5mg)

  • FOLFOXDrug

    2 hour IV infusion of oxaliplatin, folinic acid, and fluorouracil followed by a continuous 46-hour infusion of fluorouracil every two weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS)Time frame: approximately 6 months

Locations

40 sites in 3 countries. Site status is shown where the registry gives one.

  • The University of Arizona Cancer Center

    Tucson, Arizona

  • UCLA

    Los Angeles, California

  • Florida Cancer Specialists & Research Institute (FCS)

    Cape Coral, Florida

  • Florida Cancer Specialists & Research Institute

    Fleming Island, Florida

  • Florida Cancer Specialists & Research Institute

    Gainesville, Florida

  • Miami Cancer Institute

    Miami, Florida

  • Florida Cancer Specialists & Research Institute

    Wellington, Florida

  • Hematology Oncology Clinic

    Baton Rouge, Louisiana

  • Center for Cancer and Blood Disorders

    Bethesda, Maryland

  • Oncology Hematology Associates - Springfield

    Springfield, Missouri

  • Northwell Health

    Lake Success, New York

  • New York University

    New York, New York

  • Cornell University

    New York, New York

  • Mount Sinai Medical Center - New York

    New York, New York

  • White Plains Hospital

    White Plains, New York

  • Messino Cancer Centers

    Asheville, North Carolina

  • Duke University Medical Center

    Durham, North Carolina

  • Wake Forest University

    Winston-Salem, North Carolina

  • Prisma Health Cancer Institute - Faris

    Greenville, South Carolina

  • Sanford Cancer Center

    Sioux Falls, South Dakota

  • Tennessee Oncology

    Chattanooga, Tennessee

  • SCRI Oncology Partners

    Nashville, Tennessee

  • Tennessee Oncology

    Nashville, Tennessee

  • MultiCare Tacoma General Hospital

    Tacoma, Washington

  • University of Wisconsin Hospital and Clinics

    Madison, Wisconsin

  • Universitaetsklinikum Hamburg-Eppendorf (UKE) - Universitaeres Cancer Center Hamburg (UCCH)

    Hamburg, Germany

  • Universitaetsklinikum Heidelberg (UKHD) - Nationales Centrum fuer Tumorerkrankungen Heidelberg (NCT)

    Heidelberg, Germany

  • SLK-Kliniken Heilbronn GmbH - Klinikum am Gesundbrunnen - Klinik fuer Innere Medizin III

    Heilbronn, Germany

  • Gemeinschaftspraxis fuer Haematologie und Onkologie - Magdeburg

    Magdeburg, Germany

  • Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz

    Mainz, Germany

  • Dong-A University Medical Center

    Busan, South Korea

  • Kyungpook National University Chilgok Hospital

    Daegu, South Korea

  • Gachon University Gil Medical Center

    Incheon, South Korea

  • Inha University Hospital

    Incheon, South Korea

  • CHA University - Bundang CHA General Hospital

    Seongnam-si, South Korea

  • Seoul National University Bundang Hospital

    Seongnam-si, South Korea

  • Asan Medical Center

    Seoul, South Korea

  • Samsung Medical Center

    Seoul, South Korea

  • Seoul National University Hospital

    Seoul, South Korea

  • The Catholic University of Korea - St. Vincent's Hospital

    Suwon, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.